Ironwood Pharma (IRWD) Highlights 2015 Accomplishments; Offers Five-Year Operating Goals
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall St inches lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil slides on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
- Ovintiv adds 41,000 acres in Permian and Montney deals
Ironwood Pharmaceuticals Details Strategy to Build Top-Performing Commercial Biotechnology Company
January 11, 2016 9:01 AM EST- At least $1 billion in LINZESS® (linaclotide) annual net sales expected by 2020; greater than $2 billion linaclotide U.S. peak sales potential -
- At least three additional blockbuster opportunities expected to be in later-stage development by 2017/2018 -
- Financial strength to manage core business without raising additional capital -
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ironwood... More
